CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 105 enrolled
Drug / intervention
Parathyroid hormone related protein (1-36) +2 moredrug
Likely dose
Parathyroid hormone related protein (1-36) 400 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00853723
NCT00853723Phase 2Completed
CompareCT.gov

Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis

University of Pittsburgh·interventional·Posted Mar 2, 2009·Updated Mar 24, 2016

In Brief

A Phase 2 clinical trial evaluating Parathyroid hormone related protein (1-36), Parathyroid hormone related protein(1-36), and 1 other intervention for Osteoporosis. Completed, enrolled 105 participants across 1 site.

Detailed Summary

This is a three month comparison trial of standard dose parathyroid hormone (PTH) (1-34) and two different doses of Parathyroid Hormone-related Protein (PTHrP) (1-36). The investigators want to to demonstrate that daily subcutaneous injection of PTHrP (1-36) in postmenopausal women with osteoporosis stimulates bone formation to the same or greater degree than PTH (1-34) but with less bone resorption.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2, 2009
Enrollment StartMay 1, 2009
Primary CompletionFeb 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.3 years ago

Interventions

Parathyroid hormone related protein (1-36)drug

PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months

Parathyroid hormone related protein(1-36)drug

PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months

Parathyroid hormone (1-34)drug

PTH(1-34)20 micrograms subcutaneously administered daily for 3 months